2-Phenyliminoethanethial

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Phenyliminoethanethial
• 化学式: C₈H₇NS
• 分子量: 149.21
• InChiKey: AUOICDSHGBLMFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  44.4
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Radioactive Rhodium Complexes, Preparation Methods and Uses Thereof
  申请人：Institut National de la Sante et de la Recherche Medicale (INSERM)

  公开号：US20150139901A1

  公开（公告）日：2015-05-21

  The present invention concerns radioactive rhodium complexes, their preparation methods, and their use for the radiolabelling of biomolecules, especially monoclonal antibodies.

  本发明涉及放射性铑配合物，其制备方法以及它们用于放射性标记生物分子，特别是单克隆抗体的用途。
• METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS
  申请人：Thomas Jefferson University

  公开号：US20150183748A1

  公开（公告）日：2015-07-02

  The present invention provides compostions and methods useful for treating and preventing neurodenerative disease and neurologically related disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing diseases and disorders with abnormal blood brain barrier (BBB) function, for example neurodegenerative diseases with a permeable BBB, such as but not limited to, Alzhiemer's Disease, Huntington's Disease, Parkinson's Disease and Vascular Dementia.

  本发明提供了用于治疗和预防神经退行性疾病和神经相关疾病的组合物和方法，通过抑制Lp-PLA2。这些组合物和方法对于治疗和预防具有异常血脑屏障（BBB）功能的疾病和疾病非常有用，例如具有可渗透BBB的神经退行性疾病，例如但不限于阿尔茨海默病、亨廷顿病、帕金森病和血管性痴呆。
• N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS
  申请人：Plancher Jean-Marc

  公开号：US20160000763A1

  公开（公告）日：2016-01-07

  The present invention discloses compounds of Formula (I): wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

  本发明披露了式(I)的化合物：其中式(I)中的变量如本文所述。还披露了含有这种化合物的药物组合物，并且披露了使用式(I)的化合物预防或治疗HCV感染的方法。
• Compounds Useful In Therapy
  申请人：Bryans Justin Stephen

  公开号：US20100317652A1

  公开（公告）日：2010-12-16

  The present invention provides compounds of formula (I), or pharmaceutically acceptable derivatives thereof wherein the variables Z, Q, Ring A, V, X, Y and Y′ are as defined herein, and pharmaceutical compositions comprising these compounds. The compounds of formula (I) and pharmaceutical compositions comprising them are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhoea.

  本发明提供了式(I)的化合物或其药学上可接受的衍生物，其中变量Z，Q，环A，V，X，Y和Y'如此定义，并且包含这些化合物的药物组合物。式(I)的化合物和包含它们的药物组合物可用于治疗需要V1a拮抗剂的紊乱，特别是痛经。
• Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases
  申请人：Adamson Peter

  公开号：US20130267544A1

  公开（公告）日：2013-10-10

  The present invention provides compositions and methods useful for treating and preventing ocular diseases by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing diseases and disorders such as but not limited to, macular edema, uveitis and diabetic retinopathy.